首页> 外文期刊>Journal of Veterinary Internal Medicine >Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly
【24h】

Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly

机译:立体定向放射疗法治疗与猫肢端肥大症有关的功能性垂体腺瘤

获取原文
           

摘要

Background Conventional fractionated radiotherapy has been shown to be partially effective for management of pituitary tumors in cats that cause acromegaly and diabetes mellitus (DM), but, the efficacy and safety of stereotactic radiation therapy (SRT) as a treatment for acromegalic cats has not been described. Hypothesis Stereotactic radiation therapy is an effective and safe treatment for controlling acromegaly associated with pituitary adenomas in cats. Additionally, SRT‐treated acromegalic cats with DM will experience a decrease in insulin requirements after radiation therapy. Animals Fifty‐three client‐owned cats referred to Colorado State University for SRT to treat pituitary tumors causing poorly controlled DM secondary to acromegaly. Methods Retrospective study of cats treated for acromegaly with SRT between 2008 and 2016 at Colorado State University. Diagnosis of acromegaly was based on history, physical examination, laboratory results, and cross‐sectional imaging of the pituitary. Signalment, radiation protocol, insulin requirements over time, adverse effects, and survival were recorded. Results Median survival time was 1072 days. Of the 41 cats for which insulin dosage information was available, 95% (39/41) experienced a decrease in required insulin dose, with 32% (13/41) achieving diabetic remission. Remission was permanent in 62% (8/13) and temporary in 38% (5/13) cats. Median duration to lowest insulin dose was 9.5 months. Of the treated cats, 14% developed hypothyroidism and required supplementation after SRT. Conclusions Stereotactic radiation therapy is safe and effective for treating cats with acromegaly. Cats treated with SRT have improved survival time and control of their DM when compared to previously reported patients treated with non‐SRT.
机译:背景技术传统的分段放疗已被证明可有效治疗引起肢端肥大症和糖尿病(DM)的猫的垂体瘤,但立体定向放射疗法(SRT)作为肢端肥大猫的治疗方法的疗效和安全性尚未得到证实描述。假设立体定向放射疗法是一种控制猫垂体腺瘤相关肢端肥大症的有效且安全的治疗方法。此外,经SRT治疗的肢端肥大猫患有DM,放疗后胰岛素需求量将减少。动物有53只客户拥有的猫被转诊至科罗拉多州立大学(SRT),用于治疗垂体瘤,该垂体瘤导致继发于肢端肥大症的DM控制不良。方法对科罗拉多州立大学2008年至2016年间接受SRT肢端肥大症治疗的猫进行回顾性研究。肢端肥大症的诊断基于病史,体格检查,实验室检查结果和垂体横截面影像。记录信号,放射方案,随时间推移的胰岛素需求量,不良反应和生存率。结果中位生存时间为1072天。在可获得胰岛素剂量信息的41只猫中,有95%(39/41)的猫需要的胰岛素剂量减少了,其中32%(13/41)的糖尿病得到了缓解。在62%(8/13)的猫中永久缓解,在38%(5/13)的猫中暂时缓解。最低胰岛素剂量的持续时间中位数为9.5个月。在接受治疗的猫中,有14%的人出现甲状腺功能减退,需要在SRT后补充。结论立体定向放射疗法治疗猫肢端肥大症是安全有效的。与先前报道的非SRT治疗的患者相比,接受SRT治疗的猫的生存时间和对DM的控制得以改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号